Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Federal Trade Commission
Deloitte
Julphar
McKesson
Dow
Covington
Express Scripts
US Department of Justice
AstraZeneca

Generated: August 21, 2017

DrugPatentWatch Database Preview

NASONEX Drug Profile

« Back to Dashboard

Which patents cover Nasonex, and when can generic versions of Nasonex launch?

Nasonex is a drug marketed by Merck Sharp Dohme and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

The generic ingredient in NASONEX is mometasone furoate. There are twenty-nine drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the mometasone furoate profile page.

Summary for Tradename: NASONEX

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list4
Bulk Api Vendors: see list49
Clinical Trials: see list44
Patent Applications: see list4,772
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:NASONEX at DailyMed

Pharmacology for Tradename: NASONEX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme
NASONEX
mometasone furoate
SPRAY, METERED;NASAL020762-001Oct 1, 1997ABRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: NASONEX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme
NASONEX
mometasone furoate
SPRAY, METERED;NASAL020762-001Oct 1, 1997► Subscribe► Subscribe
Merck Sharp Dohme
NASONEX
mometasone furoate
SPRAY, METERED;NASAL020762-001Oct 1, 1997► Subscribe► Subscribe
Merck Sharp Dohme
NASONEX
mometasone furoate
SPRAY, METERED;NASAL020762-001Oct 1, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: NASONEX

Drugname Dosage Strength RLD Submissiondate
mometasone furoateNasal Spray50 mcg/ SprayNasonex8/7/2009
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Medtronic
McKinsey
Cipla
UBS
Moodys
McKesson
Daiichi Sankyo
Accenture
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot